Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Study in Patients With Chorioretinal Vascular Disease to Evaluate an Aflibercept (EYLEA) Prefilled Syringe

Trial Profile

A Study in Patients With Chorioretinal Vascular Disease to Evaluate an Aflibercept (EYLEA) Prefilled Syringe

Not yet recruiting
Phase of Trial: Phase IV

Latest Information Update: 14 Dec 2018

At a glance

  • Drugs Aflibercept (Primary)
  • Indications Age-related macular degeneration; Diabetic macular oedema; Diabetic retinopathy; Retinal vein occlusion
  • Focus Therapeutic Use
  • Sponsors Regeneron Pharmaceuticals
  • Most Recent Events

    • 14 Dec 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top